

Aurobindo Pharma wins FDA approval for new generic

02 March 2016 | News | By BioSpectrum Bureau

Aurobindo Pharma wins FDA approval for new generic



Aurobindo Pharma has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Acetylcysteine Injection, 6g/30 mL (200 mg/mL) single-dose vials. The product is expected to be launched in Q1 FY16-17.

The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Acetadote Injection, 6 g/30 mL, of Cumberland Pharmaceuticals.

Acetylcysteine Injection is an antidote for acetaminophen (non-aspirin pain reliever or analgesic) overdose indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen.

The approved product has an estimated market size of \$28 million for the twelve months ending December 2015 according to IMS.